Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in South Korea / NCT07673822
Enrolling by invitation Observational

Prevalence and Overlap of Cardiovascular, Kidney, and Metabolic Diseases in Korea: A Population-based Study

NCT07673822 · tracked via the Priya Life Science South Korea tracker
Sponsor
Novo Nordisk A/S
Phase
Observational
Started
2026-06-08
Last updated
2026-06-29

Condition(s) studied

Diabetes Mellitus, Type 2ObesityChronic Kidney DiseaseCardiovascular Risk

Investigational drug(s) / intervention(s)

No treatment given

No treatment given: No treatment given

Study summary

This study tests the prevalence and characteristics of overlapping obesity, type 2 diabetes (T2D), cardiovascular disease (CVD), chronic kidney disease (CKD), and metabolic dysfunction-associated steatotic liver disease \[MASLD/Metabolic Dysfunction-Associated Steatohepatitis (MASH)\], osteoarthritis, hypertension, and dyslipidemia. The purpose of the study is to measure how common cardiovascular, kidney, and metabolic diseases are in the Korean adult population and how often they occur together (overlap) over time (2013-2023). Participants will not receive any study medicine as this is an observational analysis of existing survey data. The study does not involve a new investigational drug; it analyses health and outcome data collected in routine practice and national surveys.

Eligibility

Sex
ALL
Min age
19 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * For an eligible participant, all inclusion criteria must be answered "yes". Primary Analysis: 1. Enrolled in the Korean National Health Insurance Service (NHIS) with valid insurance eligibility during the assessment year. 2. Adults aged 19 years or older at the index date (January 1 of each assessment year, annually from 2013 to 2023). Secondary Analysis (Subgroup Cohorts): 1. Enrolled in the Korean National Health Insurance Service (NHIS) with valid insurance eligibility during the cohort entry year. 2. Adults aged 19 years or older at the cohort entry date (i.e., the index date defined per the relevant subgroup cohort in) (per the SAP). 3. Meets the operational definition of the index disease or state for one of the four pre-specified subgroup cohorts (MASLD, HF, CKM stage, or High obesity) (per the SAP). Exclusion Criteria: * For an eligible participant, all exclusion criteria must be answered "no". Primary Analysis: 1. Individuals with missing age or sex information in the NHIS database. 2. Individuals with less than 1 year of continuous enrollment prior to the index date (to ensure adequate lookback period for disease identification). Secondary Analysis (Subgroup Cohorts) 1. Individuals with missing age or sex information in the NHIS database. 2. Individuals with less than 1 year of continuous NHIS enrollment prior to the cohort entry date (to ensure adequate washout for incident-case ascertainment). 3. Individuals with prior record of respective disease within the 1-year lookback window

Primary outcome measure(s)

  • Proportion of participants with obesity (BMI ≥25 kilograms per square meter (kg/m^2)) — 2013-2018 (Annually)
    Measured in proportion (%).
  • Proportion of participants with T2D — 2013-2018 (Annually)
    Measured in proportion (%).
  • Proportion of participants with hypertension — 2013-2018 (Annually)
    Measured in proportion (%).
  • Proportion of participants with dyslipidemia — 2013-2018 (Annually)
    Measured in proportion (%).
  • Proportion of participants with CVD (ASCVD, HF with atrial fibrillation, HF without atrial fibrillation) — 2013-2018 (Annually)
    Measured in proportion (%).
  • Proportion of participants with CKD — 2013-2018 (Annually)
    Measured in proportion (%).
  • Proportion of participants with MASLD; at-risk Metabolic Dysfunction-Associated Steatohepatitis (MASH)(within MASLD) — 2013-2018 (Annually)
    Measured in proportion (%).
  • Proportion of participants with Osteoarthritis (OA) — 2013-2018 (Annually)
    Measured in proportion (%).
  • Multi-disease overlap (≥2, ≥3 conditions) — 2013-2018 (Annually)
    Measured in proportion (%).
  • Patient characteristics in obesity/diabetes-anchored strata — 2013-2018 (Annually)
    Measured as descriptive statistics.

Trial sites (1)

FacilityCityRegionStatus
Novo Nordisk Pharma Korea, Ltd. Seoul South Korea

More Novo Nordisk A/S trials in South Korea

A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy Recruiting
Regulatory Post Marketing Surveillance (rPMS) Study of Ozempic (Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea Enrolling by invitation
A Research Study Looking at How Safe Somapacitan is and How Well it Works in Children Who Need Help to Grow - REAL 9 Active, not recruiting
WEgovy Real World Assessment of Weight Loss in Korea Enrolling by invitation
A Research Study to Compare Somapacitan Once a Week With Norditropin® Once a Day in Children Who Need Help to Grow Active, not recruiting

Other trials for the same condition

EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease Recruiting
Regulatory Post Marketing Surveillance (rPMS) Study of Ozempic (Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea Enrolling by invitation
A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight Recruiting
WEgovy Real World Assessment of Weight Loss in Korea Enrolling by invitation
Long-Term Follow-up of Patients With Chronic Kidney Disease Treated With Cellgram-CKD Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07673822 on ClinicalTrials.gov ↗ ← All trials in South Korea